Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RESEARCH TOOLSreports
RCKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.33 - $31.47
Previous CloseN/A
Volume339.48K
Average Volume (3M)1.47M
Market Cap
$1.15B
Enterprise Value$1.53B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 06, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding106,337,080
10 Day Avg. Volume1,217,580
30 Day Avg. Volume1,474,054
Standard Deviation0.18
R-Squared0.08
Alpha-0.00831
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-215.43
Enterprise Value/Ebitda-6.19
Forecast
1Y Price Target
$36.33Price Target Upside232.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Clinical DataAll Ph1 patients met the pivotal Ph2 primary endpoint, achieving normalized Hgb levels and requiring no more RBC transfusions up to 36 months after RP-L301 infusion.
Product DevelopmentRocket Pharma has 5+ potentially best/first-in-class, curative gene therapies in the clinic for devastating/fatal rare diseases with no approved therapies.
Regulatory ApprovalRCKT has aligned with the FDA on an accelerated approval pathway for RP-L301.
Bears Say
Financial ImpactApproval for leukocyte adhesion deficiency type I treatment has been delayed to 2025, impacting financial expectations.
Market RisksThere are risks such as the need to develop the Danon market, management execution, and long-term safety concerns.
Stock OfferingThe public offering results in gross proceeds of $165 million with an underwriter’s option for additional shares.
---
Ownership Overview
34.67% Insiders
22.53% Mutual Funds
0.51% Other Institutional Investors
30.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $9.33 and its highest was $31.47 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Rocket Pharmaceuticals’s market cap is $1.15B.
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 13 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.75 by $0.04.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -0.72.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 106,337,080 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.75. Following the earnings report the stock price went up 1.159%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Currently, no hedge funds are holding shares in RCKT
---
Rocket Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.33 (232.69% Upside)
$36.33 (232.69% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $245.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.61%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
-34.25%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
RCKT Stock 12 Month Forecast
Average Price Target
$36.33
▲(232.69% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+11.35%
reiterated a buy rating 3 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +11.35% per trade.
---